Literature DB >> 11369913

Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo.

L Scherschun1, J J Kim, H W Lim.   

Abstract

BACKGROUND: The treatment of vitiligo remains a challenge.
OBJECTIVE: The purpose of this article is to review our results and experience with narrow-band ultraviolet (UV) B phototherapy for vitiligo.
METHODS: This is a retrospective analysis of our experience and results with patients with vitiligo who were treated with narrow-band UVB between November 1998 and November 1999. Narrow-band UVB phototherapy was given as monotherapy 3 times a week. The starting dose was 280 mJ/cm(2), with 15% dose increments at each subsequent treatment.
RESULTS: Seven patients were able to be evaluated for the purposes of this analysis. Their ages ranged from 19 to 59 years (mean, 37.6 years). Three patients had Fitzpatrick skin phototype IV and V, and 4 had phototypes II and III. Five of the 7 patients achieved more than 75% repigmentation with a mean of 19 treatments; the mean duration of disease was 13 months. The remaining two patients had 50% and 40% repigmentation after 46 and 48 treatments, respectively. Their mean duration of disease was 132 months. Adverse effects were mild erythema and pruritus.
CONCLUSION: This treatment protocol resulted in rapid repigmentation in many patients, including those with skin phototypes IV and V. In accordance with previous studies, this report indicates that narrow-band UVB is a useful and well-tolerated therapy for vitiligo.

Entities:  

Mesh:

Year:  2001        PMID: 11369913     DOI: 10.1067/mjd.2001.114752

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  16 in total

Review 1.  Hypopigmentary skin disorders: current treatment options and future directions.

Authors:  Anke Hartmann; Eva-B Bröcker; Jürgen C Becker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Targeted Broadband UVB Phototherapy forthe Treatment of Localized Vitiligo.

Authors:  Jeong Eun Kim; Hyo Hyun Ahn; Young Chul Kye
Journal:  Ann Dermatol       Date:  2008-09-30       Impact factor: 1.444

3.  Keratinocyte-derived laminin-332 promotes adhesion and migration in melanocytes and melanoma.

Authors:  Heesung Chung; Eun-Kyung Suh; Inn-Oc Han; Eok-Soo Oh
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

4.  Differential roles of T-cell subsets in regulation of ultraviolet radiation induced cutaneous photocarcinogenesis.

Authors:  Tahseen H Nasti; Omer Iqbal; Iman A Tamimi; James T Geise; Santosh K Katiyar; Nabiha Yusuf
Journal:  Photochem Photobiol       Date:  2010-12-08       Impact factor: 3.421

5.  Short-term effects of 308-nm xenon-chloride excimer laser and narrow-band ultraviolet B in the treatment of vitiligo: a comparative study.

Authors:  Seok-Beom Hong; Hyun-Ho Park; Mu-Hyoung Lee
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

6.  Narrow band-ultraviolet B versus clobetasol propionate foam in the treatment of vitiligo: a retrospective study.

Authors:  Giuseppe Stinco; Giusto Trevisan; Cinzia Buligan; Giorgia Gregoraci; Sergio De Marchi; Nicola di Meo; Pasquale Patrone
Journal:  Dermatol Ther (Heidelb)       Date:  2013-06-04

7.  Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial.

Authors:  Orest Szczurko; Neil Shear; Anna Taddio; Heather Boon
Journal:  BMC Complement Altern Med       Date:  2011-03-15       Impact factor: 3.659

8.  Efficacy of suction blister epidermal graft without phototherapy for locally stable and resistant vitiligo.

Authors:  Masoud Maleki; Mahnaz Banihashemi; Vahid Sanjari
Journal:  Indian J Dermatol       Date:  2012-07       Impact factor: 1.494

9.  Efficacy of targeted narrowband ultraviolet B therapy in vitiligo.

Authors:  Imran Majid
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

Review 10.  Vitiligo in Children: A Review of Conventional Treatments.

Authors:  Serena Gianfaldoni; Uwe Wollina; Georgi Tchernev; Jacopo Lotti; Katlein França; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2018-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.